5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H2 2018
Summary
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes clos
- Introduction
- Global Markets Direct Report Coverage
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Overview
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Companies Involved in Therapeutics Development
- Adamed Sp z oo
- Astellas Pharma Inc
- Avineuro Pharmaceuticals Inc
- H. Lundbeck AS
- Johnson & Johnson
- Reviva Pharmaceuticals Inc
- Sumitomo Dainippon Pharma Co Ltd
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Drug Profiles
- ADN-1184 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ADN-3662 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AVN-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- DDD-028 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- JNJ-18038683 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- lurasidone hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RP-5063 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SERx-519 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for Migraine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Target 5-HT7R for Sleep Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- vortioxetine hydrobromide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Dormant Products
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Discontinued Products
- 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Product Development Milestones
- Featured News & Press Releases
- Oct 22, 2018: U.S. Food and Drug Administration approves expansion of Trintellix (vortioxetine) label
- Oct 22, 2018: New Data Added to TRINTELLIX (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
- Sep 28, 2018: Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
- Jun 08, 2018: Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
- May 02, 2018: TRINTELLIX (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
- May 02, 2018: Sunovion to Presents Data on Latuda at the 2018 American Psychiatric Association Annual Meeting
- Apr 20, 2018: Sunovion Announces Health Canada Approval of Latuda (lurasidone HCl) to Treat Adolescents (13 to 17 years of age) with Bipolar Depression
- Apr 18, 2018: Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA
- Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- Mar 06, 2018: Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
- Feb 23, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in US
- Feb 14, 2018: Sumitomo Dainippon Pharma Filed Patent Infringement Lawsuits Regarding LATUDA in the United States
- Jan 10, 2018: Avineuro Pharmaceuticals Reported Phase Ib Trial Results of AVN-101
- Dec 04, 2017: Lundbeck’s Brintellix approved in China
- Oct 27, 2017: Sunovion Presents Data from Phase 3 Studies of Latuda (lurasidone HCl) in Children and Adolescents with Bipolar Depression
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Indication, H2 2018
- Number of Products under Development by Companies, H2 2018
- Products under Development by Companies, H2 2018
- Products under Development by Companies, H2 2018 (Contd..1), H2 2018
- Number of Products under Investigation by Universities/Institutes, H2 2018
- Products under Investigation by Universities/Institutes, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Stage and Route of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
- Pipeline by Adamed Sp z oo, H2 2018
- Pipeline by Astellas Pharma Inc, H2 2018
- Pipeline by Avineuro Pharmaceuticals Inc, H2 2018
- Pipeline by H. Lundbeck AS, H2 2018
- Pipeline by Johnson & Johnson, H2 2018
- Pipeline by Reviva Pharmaceuticals Inc, H2 2018
- Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
- Dormant Projects, H2 2018
- Discontinued Products, H2 2018
- List of Figures
- Number of Products under Development by Stage of Development, H2 2018
- Number of Products under Development by Therapy Areas, H2 2018
- Number of Products under Development by Top 10 Indications, H2 2018
- Number of Products by Stage and Mechanism of Actions, H2 2018
- Number of Products by Routes of Administration, H2 2018
- Number of Products by Stage and Routes of Administration, H2 2018
- Number of Products by Stage and Molecule Type, H2 2018
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook